Parameter | INT | NON-INT | p | |
---|---|---|---|---|
N | 39 | 159 | - | |
Male : female | 25:14 | 77:82 | 0.079 | |
Age | 69 (36–81) | 67 (30–89) | 0.569 | |
Distant metastasis (M1) | 1 (3%) | 6 (4%) | 0.714 | |
Neoadjuvant therapy | 1 (3%) | 13 (8%) | 0.220 | |
Resection | PPPD | 31 (80%) | 132 (83%) | 0.701 |
Whipple | 6 (15%) | 17 (11%) | ||
TPE | 2 (5%) | 10 (6%) | ||
PVR | 8 (21%) | 54 (34%) | 0.105 | |
Perioperative mortality | 2 (5%) | 5 (3%) | 0.548 | |
Tumor size (mm) | 23 (1–320) | 25 (3–70) | 0.779 | |
Grade G3/4 | 6 (15%) | 66 (42%) | 0.002 | |
pT Stage 3/4 | 21 (54%) | 134 (84%) | 0.000 | |
pN Stage 1/2 | 16 (41%) | 116 (73%) | 0.000 | |
Lymph node ratio (LNR) | .00 (.00-.58) | .12 (.00-.86) | 0.018 | |
Lymphangiosis (L1) | 12 (31%) | 75 (47%) | 0.064 | |
Hemangiosis (V1) | 1 (3%) | 28 (18%) | 0.017 | |
Perineural invasion (Pn1) | 13 (33%) | 100 (63%) | 0.001 | |
Positive resection margin | 3 (8%) | 48 (30%) | 0.004 | |
Location | PDAC / DBDAC | 16 (41%) | 133 (84%) | 0.000 |
AMPAC / DUOAC | 23 (59%) | 26 (16%) | ||
% CK7 | 85 (0–100) | 90 (0–100) | 0.070 | |
% CK20 | 45 (0–100) | 0 (0–100) | 0.000 | |
% nuclear CDX2 | 80 (0–100) | 0 (0–100) | 0.000 | |
Associated precursor lesion | Adenoma | 8 (21%) | 12 (8%) | 0.016 |
IPMN | 3 (8%) | 8 (5%) | 0.516 |